Physician profile
Patrick B Murphy
NPI 1487672291
$11,432.79
in general payments reported to CMS, 2019-2025
52 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,709 · 2020: $1,170 · 2021: $1,589 · 2022: $1,858 · 2023: $1,547 · 2024: $225 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878 · Long Term Medical Supply Or Device Loan: $167 · Education: $62.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.17 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $62.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,812.69 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,439.06 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $1,146.80 | 2022-2024 | |
| Janssen Biotech, INC. | $787.09 | 2019-2025 | Darzalex, Imbruvica, Erleada |
| Merck Sharp & Dohme LLC | $597.92 | 2019-2024 | Keytruda, Lynparza |
| Amgen INC. | $564.12 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $546.59 | 2019-2025 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $493.74 | 2019-2023 | Reblozyl, Opdivo, Opdualag |
| Daiichi Sankyo INC. | $373.34 | 2019-2025 | Injectafer, Enhertu |
| Seagen INC. | $369.17 | 2019-2023 | Tukysa, Tivdak |
| Incyte Corporation | $276.69 | 2019-2023 | Monjuvi, Pemazyre |
| Celgene Corporation | $223.06 | 2019-2024 | Reblozyl |
| Lilly USA, LLC | $218.88 | 2019-2020 | |
| Pfizer INC. | $199.52 | 2019-2023 | |
| Tg Therapeutics, INC. | $188.11 | 2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.